WALD — Waldencast plc

Summary of Waldencast Q1 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Revenue: $65.4 million, a decline of 4.1% year-over-year.
• Adjusted Gross Profit Margin: 76.4%, up 10 basis points from the previous year.
• Adjusted EBITDA: $4.4 million, representing a margin of 6.7%.
• Milk Makeup Revenue: Declined 15.1%, with a strong domestic performance offset by international challenges.
• Obagi Medical Revenue: Increased 7.1% to $36.2 million, but faced out-of-stock issues.
• Cash Position: $10.8 million, with an additional $22.5 million available on a revolving credit facility.
• Net Debt: Increased to $172.1 million from $154.2 million at the end of 2024.

2. Strategic Updates and Business Highlights

• Brand Performance: Milk Makeup's Hydro Grip Gel Skin Tint launched successfully, generating significant consumer interest and sales. The brand also entered Ulta Beauty, contributing to high single-digit growth in US retail sales.
• Obagi Medical: Focused on supply chain transformation to enhance operational efficiency, including consolidating logistics providers.
• Innovation Pipeline: Both brands are introducing new products aimed at expanding market share and consumer engagement.
• Digital Growth: Strong performance in digital channels for both brands, with Milk Makeup's launch at Ulta expected to attract new customers.

3. Forward Guidance and Outlook

• Revenue Growth Target: Mid-teens growth for the full fiscal year 2025.
• Adjusted EBITDA Margin: Expected in the mid to high-teens.
• Key Growth Drivers: Continued innovation, expansion in retail and digital channels, and improved product availability.

4. Challenges and Points of Concern

• Declining Revenue: Overall revenue decline attributed to tough comparisons with prior year growth and a decelerating beauty market.
• Supply Chain Issues: Out-of-stock situations for key products at Obagi Medical and Milk Makeup, impacting sales.
• International Performance: Milk Makeup's international sales faced challenges due to tough year-over-year comparisons and delayed product launches.
• Macroeconomic Pressures: Potential impacts from softer consumer sentiment and tariffs, although the company believes it can manage tariff-related cost increases.

5. Notable Q&A Insights

• Supply Chain Restructuring: Management acknowledged the need for improved flexibility and responsiveness in the supply chain, which has faced disruptions during the transition.
• Physician Channel Performance: No significant slowdown in demand was noted; challenges were attributed to changes in the Amazon distribution model rather than fewer physician visits.
• Pricing Strategy: Management is monitoring tariff impacts and is prepared for selective price increases if necessary, maintaining that their exposure to China is limited.
• Marketing Investments: Increased focus on top-of-funnel advertising for Milk Makeup and expanding consumer outreach for Obagi Medical, aiming to drive brand awareness and sales.

Overall, while Waldencast faced challenges in Q1 2025, management remains optimistic about the future, citing strong brand potential and strategic initiatives aimed at driving growth.